secwatch.observer — SEC 8-K summary
======================================

Issuer:     ULIXE CORP. (—)
CIK:        0001842138
Form:       8-K
Filed at:   2026-06-25T21:20:48+00:00
Accession:  0001829126-26-006877
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ulixe Corp sells Ulixe Nova S.r.l. for €1.00; restructuring ahead of Nasdaq uplisting
--------------------------------------------------------------------------------

- Sold 100% equity in Ulixe Nova to Condotti Capital S.r.l. for nominal €1.00 on June 18, 2026.
- Divestiture driven by Ulixe Nova's financial constraints and capital needs; part of strategic reorganization.
- Post-sale structure: Ulixe Italy owns Dale Consulting, Ulixe Pharma, MBSNet; MBSNet owns Fintexa.
- Ulixe Corp previously acquired MBSNet (Nov 2025) to enhance fintech and digital payments capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842138/000182912626006877/0001829126-26-006877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842138/000182912626006877/ulixecorp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-006877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer